Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2023 08:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer

Austin, TX, March 08, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
February 28, 2023 08:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer

Austin, TX, Feb. 28, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
February 22, 2023 08:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Recruits the Ellis Fischel Cancer Center at the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam® for Bone Cancer

Austin, TX, Feb. 22, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
January 23, 2023 08:30 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences to Present at the Emerging Growth Conference on Wednesday, January 25, 2023

QSAM invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Austin, TX, Jan. 23, 2023...
January 10, 2023 07:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Provides 2022 Update and 2023 Milestones to Shareholders

AUSTIN, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
November 15, 2022 08:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Further Progress Demonstrated in Clinical Program Evaluating CycloSam® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer AUSTIN, Texas, Nov. 15, 2022 (GLOBE...
October 26, 2022 08:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer

Austin, TX, Oct. 26, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
August 16, 2022 08:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Progress Shown in Phase 1 Clinical Program Evaluating CycloSam® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- QSAM...
May 17, 2022 08:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update

Dosed First Patient in Phase 1 Clinical Program Evaluating CycloSam® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer Austin, TX, May 17, 2022 (GLOBE NEWSWIRE) -- QSAM...
April 28, 2022 07:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Doses First Patient in its Clinical Trial for Cyclosam®, Radiopharmaceutical Drug Candidate for the Treatment of Bone Cancer

Austin, TX, April 28, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right